

Supplementary Table S1. Clinical and demographic features of 58 COVID19 patients.

Features	Patients n=58 (%)	GROUP A Hydroxy- chloroquine n=26 (44.8)	GROUP B Hydroxy- chloroquine and azithromycin n=15 (25.9)	GROUP C No Hydroxy- chloroquine and azithromycin n=17 (29.3)	A-B-C p-value	A-B p-value	B-C p-value	A-C p-value
Age years (IQR)	70.5 (25)	75 (21.5)	66 (19)	73 (42.5)	NS	-	-	-
Female	23 (39.7)	14 (53.8)	5 (33.3)	6 (35.3)	-	NS	NS	NS
Comorbidities	50 (86)	23 (88.5)	12 (80)	15 (88)	-	NS	NS	NS
Hypertension	24 (48)	17 (63.4)	3 (20)	9 (52.9)	-	0.005	0.06	NS
Diabetes	13 (26)	8 (30.8)	3 (20)	4 (23.5)	-	NS	NS	NS
Cardiovascular disease	13 (22.4)	7 (26.9)	1 (6.7)	5 (29.4)	-	NS	NS	NS
COPD or asthma	9 (15.5)	5 (19)	4 (26.7)	0	-	NS	-	-
Malignancy	7 (12.1)	2 (7.7)	3 (20)	2 (11.7)	-	NS	NS	NS
Thyroid disease	8 (13.8)	5 (19)	0	3 (17.6)	-	-	-	NS
Cerebrovascular disease	3 (5.1)	2 (7.7)	0	1 (5.9)	-	-	-	NS
Chronic kidney disease	5 (8.6)	2 (7.7)	0	3 (17.6)	-	-	-	NS
Onset illness prior to test (IQR)	5 days (9.25)	6 days (9)	6 days (6)	0 days (3.75)	0.008	NS	0.017	0.004
Contact with COVID19 (IQR)	27 (46.6)	15 (57.7)	4 (26.7)	8 (47)	-	NS	NS	NS
Signs and symptoms median (IQR)								
Fever	42 (72.4)	22 (84.6)	11 (73.3)	9 (52.9)	-	NS	NS	0.02
Dyspnea	28 (48.3)	17 (65.4)	6 (40)	5 (29.4)	-	NS	NS	0.02
Cough	21 (36.2)	14 (53.8)	3 (20)	4 (23.5)	-	0.03	0.06	0.049
Diarrhoea	6 (10.3)	4 (15.4)	0	2 (11.7)	-	-	-	NS
Headache	4 (6.9)	0	3 (20)	1 (5.9)	-	-	NS	-
Chest pain	3 (5.2)	1 (3.8)	1 (6.7)	1 (5.9)	-	NS	NS	0.1
Ageusia/Anosmia	3 (5.2)	1 (3.8)	2 (13.3)	0	-	NS	-	-
HRCT thorax: Bilateral ground glass opacity	49 (84.5)	24 (92.3)	12 (80)	13 (76.5)	-	NS	0.06	NS
Negativisation naso-oropharyngeal swabs for SARS-CoV-2	26 (52)	15 (57.7)	7 (46.7)	6 (35.3)	-	NS	NS	0.07
Time of negativisation, median (IQR)	21 days (15.25)	21 days (19)	20 days (17)	15.5 days (16.7)	NS	-	-	-
Baseline laboratory values, median (IQR)								
Lymphocyte count, cells/L	1045 (855)	880 (610)	1114 (900)	1070 (1020)	0.05	-	-	-
Lactate dehydrogenase, U/L	287 (121)	290 (114.8)	274 (136)	289 (151)	NS	-	-	-
Ferritin ug/L	403 (625)	596 (556)	301 (423)	397 (610)	0.16	-	-	-
PCR ug/L	30800 (83725)	38550 (87650)	13700 (39900)	29500 (76050)	NS	-	-	-
D-dimer mg/L	1059 (1557)	1173 (3439)	1180 (1626)	571 (813)	NS	-	-	-
PaO2:FIO2, mm Hg	351 (172)	287.5 (152)	404 (124)	400 (156.5)	0.025	NS	NS	0.01
Complications								
Arrhythmia	4 (6.9)	2	2	0	-	NS	-	-
ARDS	6 (10.3)	5	1	0	-	NS	-	-
ALI	17 (29.3)	11	3	3	-	NS	NS	NS
Tisdale score at treatment initiation								
<7	50 (86.2)	24	13	13	-	NS	NS	NS
7-10	8 (13.8)	2	2	4	-	NS	NS	NS
>10	0	0	0	0	-	-	-	-
1 QTc-prolonging agent	17 (29.3)	8	2	7	-	NS	NS	NS
≥2 QTc-prolonging agents	7 (12)	0	2	5	-	-	NS	-
Loop diuretic	8 (13.8)	4	2	2	-	NS	NS	NS
Baseline QTc ≥450 ms	13 (22.4)	4	3	6	-	NS	NS	NS
Heart failure	7 (12)	3	1	3	-	NS	NS	NS
Acute coronary syndrome	2 (3.5)	0	1	1	-	-	NS	-
Serum potassium <3.5 mEq / magnesium <2.0 mg/dl at QTc peak	0	0	0	0	-	-	-	-
Baseline QTc, median (IQR)	413 (47)	409 (69)	418 (49.8)	-	0.03	NS	-	-
During treatment QTc, median (IQR)	432 (52)	442.5 (57.5)	420 (65)	-	-	NS	-	-
Post-treatment/follow up QTc peak, median (IQR)	432 (36.25)	436 (60)	421 (54)	444 (52)	NS	-	-	-
QTc prolongation	15 (25.9)	8 (30.8)	2 (13.3)	5 (29.4)	-	NS	NS	NS